-
Home > About Us
About Us
-
Naurex, Inc. is developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the NMDA receptor. Using these discoveries, Naurex has generated novel chemical drug classes known as Glycine Site Functional Partial Agonists (GFPAs). The company is developing two drug programs based on its GFPA NMDA modulators – GLYX-13 and the NRX-1050 series. GLYX-13 has shown promising signs of robust antidepressant activity with excellent safety in preclinical studies. It is currently being assessed in a Phase I clinical trial in treatment-resistant depression. The second generation NRX-1050 series of compounds is advancing rapidly in preclinical development.
